Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Harvard Business School
Merck
Express Scripts
Dow

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Patent: 10,035,848

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,035,848
Title:Antibody targeting cell surface deposited complement protein C3d and use thereof
Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
Inventor(s): Wiestner; Adrian U. (Bethesda, MD), Skarzynski; Martin W. (North Bethesda, MD), Lindorfer; Margaret A. (Keswick, VA), Taylor; Ronald P. (Keswick, VA), Rader; Christoph (Jupiter, FL), Vire; Berengere (Le Cres, FR)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA)
Application Number:15/110,577
Patent Claims:see list of patent claims

Details for Patent 10,035,848

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) 2034-01-08 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) 2034-01-08 RX Orphan search
Genentech Inc OCREVUS ocrelizumab INJECTABLE;INJECTION 761053 001 2017-03-28   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) 2034-01-08 RX search
Genentech GAZYVA obinutuzumab INJECTABLE;INJECTION 125486 001 2013-11-01   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) 2034-01-08 RX search
Glaxo Grp Ltd ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) 2034-01-08 RX Orphan search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) 2034-01-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Colorcon
Medtronic
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.